| Title | Response |
| Number of Patients Screened | 21 |
| Number of Patients Enrolled | 6 |
| Number of Patients Evaluable for Toxicity | 6 |
| Number of Patients Evaluated for Efficacy | 2 |
| Evaluation Method | RECIST 1.1 |
| Response Assessment CR | n = 0 (0%) |
| Response Assessment PR | n = 0 (0%) |
| Response Assessment SD | n = 0 (0%) |
| Response Assessment PD | n = 2 |
| Response Assessment OTHER | n = 0 (0%) |
| Title | Response |
| Number of Patients Screened | 21 |
| Number of Patients Enrolled | 6 |
| Number of Patients Evaluable for Toxicity | 6 |
| Number of Patients Evaluated for Efficacy | 2 |
| Evaluation Method | RECIST 1.1 |
| Response Assessment CR | n = 0 (0%) |
| Response Assessment PR | n = 0 (0%) |
| Response Assessment SD | n = 0 (0%) |
| Response Assessment PD | n = 2 |
| Response Assessment OTHER | n = 0 (0%) |
| Title | Response |
| Number of Patients Screened | 21 |
| Number of Patients Enrolled | 6 |
| Number of Patients Evaluable for Toxicity | 6 |
| Number of Patients Evaluated for Efficacy | 2 |
| Evaluation Method | RECIST 1.1 |
| Response Assessment CR | n = 0 (0%) |
| Response Assessment PR | n = 0 (0%) |
| Response Assessment SD | n = 0 (0%) |
| Response Assessment PD | n = 2 |
| Response Assessment OTHER | n = 0 (0%) |
| Title | Response |
| Number of Patients Screened | 21 |
| Number of Patients Enrolled | 6 |
| Number of Patients Evaluable for Toxicity | 6 |
| Number of Patients Evaluated for Efficacy | 2 |
| Evaluation Method | RECIST 1.1 |
| Response Assessment CR | n = 0 (0%) |
| Response Assessment PR | n = 0 (0%) |
| Response Assessment SD | n = 0 (0%) |
| Response Assessment PD | n = 2 |
| Response Assessment OTHER | n = 0 (0%) |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
